G. Walmsley Graham
CIK: 0001777517
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Jun 18, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
29.5K shares- - Dec 9, 2025AKRO
Akero Therapeutics, Inc.
Disposition(D)Direct9.4K shares- - Dec 9, 2025AKRO
Akero Therapeutics, Inc.
Disposition(D)Direct93K shares- - Dec 9, 2025AKRO
Akero Therapeutics, Inc.
Disposition(D)Indirect1.2M shares- - Oct 8, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct13K shares at avg. $25.20$328K - Oct 8, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct13K shares at avg. $26.32$342K - Oct 8, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct23.8K shares at avg. $19.97$476K - Oct 8, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct26K shares at avg. $23.02$599K - Oct 8, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct15K shares at avg. $8.13$122K - Jun 11, 2025OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
24.2K shares- - Jun 3, 2025AKRO
Akero Therapeutics, Inc.
Award(A)Direct9.4K shares- - Mar 27, 2025AKRO
Akero Therapeutics, Inc.
Purchase(P)Indirect50K shares at avg. $43.55$2.2M - Mar 26, 2025AKRO
Akero Therapeutics, Inc.
Purchase(P)Indirect58.7K shares at avg. $43.01$2.5M - Mar 25, 2025AKRO
Akero Therapeutics, Inc.
Purchase(P)Indirect91.3K shares at avg. $44.75$4.1M - Jan 30, 2025AKRO
Akero Therapeutics, Inc.
Purchase(P)Indirect200K shares at avg. $48.00$9.6M - Dec 17, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Indirect700.8K shares at avg. $6.75$4.7M - Dec 17, 2024OLMA
Olema Pharmaceuticals, Inc.
Purchase(P)Indirect700.8K shares at avg. $6.75$4.7M - Dec 13, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Indirect700.8K shares at avg. $6.75$4.7M - Dec 13, 2024OLMA
Olema Pharmaceuticals, Inc.
Purchase(P)Indirect700.8K shares at avg. $6.75$4.7M - Jun 4, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Indirect475K shares at avg. $14.85$7.1M - Jun 4, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Indirect700K shares at avg. $14.85$10.4M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 29,500 | - | - | Direct |
| Dec 9, 2025 |  AKRO Akero Therapeutics, Inc. | Disposition(D) | 9,398 | - | - | Direct |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | Disposition(D) | 93,000 | - | - | Direct |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | Disposition(D) | 1,200,000 | - | - | Indirect |
| Oct 8, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 13,000 | $25.20 | $327,600 | Direct |
| Oct 8, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 13,000 | $26.32 | $342,160 | Direct |
| Oct 8, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 23,832 | $19.97 | $475,925 | Direct |
| Oct 8, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 26,000 | $23.02 | $598,520 | Direct |
| Oct 8, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 15,000 | $8.13 | $121,950 | Direct |
| Jun 11, 2025 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 24,150 | - | - | Direct |
| Jun 3, 2025 | AKRO Akero Therapeutics, Inc. | Award(A) | 9,398 | - | - | Direct |
| Mar 27, 2025 | AKRO Akero Therapeutics, Inc. | Purchase(P) | 50,000 | $43.55 | $2,177,700 | Indirect |
| Mar 26, 2025 | AKRO Akero Therapeutics, Inc. | Purchase(P) | 58,691 | $43.01 | $2,524,417 | Indirect |
| Mar 25, 2025 | AKRO Akero Therapeutics, Inc. | Purchase(P) | 91,309 | $44.75 | $4,085,804 | Indirect |
| Jan 30, 2025 | AKRO Akero Therapeutics, Inc. | Purchase(P) | 200,000 | $48.00 | $9,600,000 | Indirect |
| Dec 17, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 700,761 | $6.75 | $4,730,137 | Indirect |
| Dec 17, 2024 | OLMA Olema Pharmaceuticals, Inc. | Purchase(P) | 700,761 | $6.75 | $4,730,137 | Indirect |
| Dec 13, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 700,761 | $6.75 | $4,730,137 | Indirect |
| Dec 13, 2024 | OLMA Olema Pharmaceuticals, Inc. | Purchase(P) | 700,761 | $6.75 | $4,730,137 | Indirect |
| Jun 4, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 475,000 | $14.85 | $7,053,750 | Indirect |
| Jun 4, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 700,000 | $14.85 | $10,395,000 | Indirect |
1-21 of 21 transactions
About Graham G. Walmsley
Graham G. Walmsley (SEC CIK 0001777517) files insider reports with the SEC as Director of Olema Pharmaceuticals, Inc. (OLMA) and Director of Akero Therapeutics, Inc. (AKRO).
Signal8 holds 11 ownership filings by Graham G. Walmsley, all Form 4s, filed between Nov 26, 2024 and Jun 23, 2026. Those filings report 21 transactions, from Jun 4, 2024 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Graham G. Walmsley's filings is in SAN FRANCISCO, CA.
Recent filings by Graham G. Walmsley
- Jun 18, 2026: Grant or award of OLMA derivative securities (Form 4, code A).
- Dec 9, 2025: Disposition to issuer transactions of AKRO shares (3 lines, Form 4, code D).
- Oct 8, 2025: Option exercises of AKRO shares (5 lines, Form 4, code M).
- Jun 11, 2025: Grant or award of OLMA derivative securities (Form 4, code A).
- Jun 3, 2025: Grant or award of AKRO shares (Form 4, code A).
Other insiders filing for Olema Pharmaceuticals, Inc. (OLMA)
- O'Byrne Jason, CHIEF FINANCIAL OFFICER
- Harmon Cyrus, Director
- BVF PARTNERS L P/IL, Director
- BUTITTA CYNTHIA M, Director
- Garland J. Scott, Director
- Hrustanovic Gorjan, Director